Drugs for Juvenile Glaucoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 39)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Bevacizumab |
Approved, Investigational |
Phase 4 |
|
216974-75-3 |
|
Synonyms:
216974-75-3
antiVEGF
anti-VEGF monoclonal antibody
Avastin
Avastin (TN)
bevacizumab
|
Bevacizumab
Bevacizumab (genetical recombination)
Bevacizumab (genetical recombination) (JAN)
bevacizumab-awwb
D06409
R-435
|
|
2 |
|
Angiogenesis Modulating Agents |
|
Phase 4 |
|
|
|
3 |
|
Angiogenesis Inhibitors |
|
Phase 4 |
|
|
|
4 |
|
Travoprost |
Approved |
Phase 3,Phase 1 |
|
157283-68-6 |
5282226
|
Synonyms:
(((1R)-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-dihydroxy-2-(3-hydroxy-4-(3-trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester
(+)-Fluprostenol isopropyl ester
(1R-(1alpha(Z),2beta(1E,3R*),3alpha,5alpha))-7-(3,5-Dihydroxy-2-(3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-5-heptenoic acid, 1-methylethyl ester
(Z)-7-((1R,2R,3R,5S)-3,5-Dihydroxy-2-((1E,3R)-3-hydroxy-4-((alpha,alpha,alpha-trifluoro-m-isopropyl-tolyl)oxy)-1-butenyl)cyclopentyl)-5-heptenoate
157283-68-6
5-Heptenoic acid,7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((1E,3R)-3-hydroxy-4-(3-(trifluoromethyl)phenoxy)-1-butenyl)cyclopentyl)-,1-methylethyl ester,(5Z)
AC1NQZOS
AC-6103
AL6221
AL-6221
C26H35F3O6
CHEBI:746859
CHEMBL1200799
CID5282226
D01964
DB00287
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(a,a,a-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(a,a,a-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoic acid
isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1e,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
|
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(alpha,alpha,alpha-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoic acid
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[(α,α,α-trifluoro-m-tolyl)oxy]-1-butenyl}cyclopentyl)-5-heptenoic acid
LS-173521
propan-2-yl (5Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-{(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-en-1-yl}cyclopentyl]hept-5-enoate
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]but-1-enyl]cyclopentyl]hept-5-enoate
S1554_Selleck
Travatan
Travatan (TN)
Travatan Alcon
Travatan Z
Travatan, Travoprost
Travatanz
Travoprost
Travoprost (JAN/USAN/INN)
Travoprost [USAN]
Travoprostum
Z, Travatan
ZINC04474682
|
|
5 |
|
Benzocaine |
Approved, Investigational |
Phase 3 |
|
94-09-7, 1994-09-7 |
2337
|
Synonyms:
(P-(Ethoxycarbonyl)phenylamine
06952_FLUKA
112909_ALDRICH
112909_SIAL
1333-08-0
23239-88-5
23239-88-5 (hydrochloride)
4 Aminobenzoic Acid Ethyl Ester
4-(Ethoxycarbonyl)aniline
4-(Ethoxycarbonyl)phenylamine
4-14-00-01129 (Beilstein Handbook Reference)
4-Aminobenzoate
4-Aminobenzoate ethyl ester
4-Aminobenzoic acid
4-aminobenzoic acid ethyl ester
4-amino-benzoic acid ethyl ester
4-Aminobenzoic acid ethyl ester
4-Aminobenzoic acid, ethyl ester
4-Carbethoxyaniline
71123-91-6
94-09-7
94-09-7 (Parent)
A0271
AB00051923
AC1L1DGC
AC1Q341A
AC1Q64JE
Acetate, benzocaine
Acetate, Benzocaine
AE-562/40377256
Aethoform
Aethylium paraminobenzoicum
AI3-02081
AKOS000119763
Amben ethyl ester
Americaine
Anaesthan-syngala
Anaesthesin
Anaesthesinum
Anaesthin
Anestezin
Anestezin [Russian]
Anesthesin
Anesthesine
Anesthone
AR-1H9065
Baby anbesol
Baby Anbesol
BB_SC-0019
Bensokain
Benzoak
Benzocaina
Benzocaina [INN-Spanish]
benzocaine
Benzocaine
Benzocaine (USP/INN)
Benzocaine [INN:BAN]
Benzocaine acetate
Benzocaine Acetate
Benzocaine formate
Benzocaine Formate
Benzocaine hydrobromide
Benzocaine Hydrobromide
Benzocaine hydrochloride
Benzocaine Hydrochloride
Benzocaine methanesulfonate
Benzocaine Methanesulfonate
Benzocainum
Benzocainum [INN-Latin]
Benzoic acid, 4-amino-, ethyl ester
Benzoic acid, 4-amino-, ethyl ester, hydrochloride
Benzoic acid, amino-, ethyl ester
Benzoic acid, p-amino-, ethyl ester
BPBio1_001017
BRD-K75466013-001-05-2
BRN 0638434
BSPBio_000923
BSPBio_001908
C07527
CAS-94-09-7
Caswell No. 430A
CHEBI:116735
CHEMBL278172
Chloraseptic
CID2337
D001566
D00552
DB01086
Dermoplast
Diet ayds
DivK1c_000932
E1501_SIGMA
EINECS 202-303-5
EPA Pesticide Chemical Code 097001
Ethoform
Ethoforme
Ethyl 4-aminobenzoate
Ethyl 4-aminobenzoate hydrochloride
Ethyl 4-aminobenzoic acid
Ethyl aminobenzoate
Ethyl Aminobenzoate
Ethyl aminobenzoate (JP15)
Ethyl aminobenzoate (VAN)
Ethyl aminobenzoic acid
|
Ethyl PABA
Ethyl P-aminobenzenecarboxylate
Ethyl p-aminobenzoate
Ethyl p-Aminobenzoate
Ethyl P-aminobenzoate
Ethyl P-aminobenzoic acid
Ethyl p-aminophenylcarboxylate
Ethyl p-Aminophenylcarboxylate
Ethyl P-aminophenylcarboxylate
Ethyl P-aminophenylcarboxylic acid
ethylaminobenzoate-4
Ethylester kyseliny p-aminobenzoove
Ethylester kyseliny P-aminobenzoove
Ethylester kyseliny p-aminobenzoove [Czech]
Ethylis aminobenzoas
ETHYL-P-AMINOBENZOATE
Formate, benzocaine
Formate, Benzocaine
h-4-abz-oet
HMS1570O05
HMS1920G09
HMS2091M11
HMS502O14
HSDB 7225
Hurricaine
Hydrobromide, benzocaine
Hydrobromide, Benzocaine
Hydrochloride, benzocaine
Hydrochloride, Benzocaine
I05-0204
Identhesin
IDI1_000932
KBio1_000932
KBio2_000474
KBio2_003042
KBio2_005610
KBio3_001408
KBioGR_000658
KBioSS_000474
Keloform
LS-35847
Methanesulfonate, benzocaine
Methanesulfonate, Benzocaine
MLS001331704
MLS002153970
MolPort-000-871-526
NCGC00016352-01
NCGC00094598-01
NCGC00094598-02
nchembio.182-comp4
NINDS_000932
Norcain
Norcaine
Norcainum
NSC 122792
NSC 41531
NSC41531
NSC4688
Oprea1_750694
Oprea1_827402
Orabase-b
Ora-jel
Orthesin
Otocain
Outgro
p-(Ethoxycarbonyl)aniline
P-(Ethoxycarbonyl)aniline
P-Aminobenzoate
P-Aminobenzoic acid
p-Aminobenzoic acid ethyl ester
P-Aminobenzoic acid ethyl ester
p-Aminobenzoic acid, ethyl ester
p-Aminobenzoic ethyl ester
Parathesin
Parathesin (TN)
Parathesine
p-Carbethoxyaniline
P-Carbethoxyaniline
p-Ethoxycarboxylic aniline
p-Ethoxycarboxylic Aniline
P-Ethoxycarboxylic aniline
Prestwick_991
Prestwick0_000712
Prestwick1_000712
Prestwick2_000712
Prestwick3_000712
Slim mint gum
SMR000059025
Solarcaine
Solu H
SPBio_000134
SPBio_002844
Spectrum_000074
SPECTRUM1500139
Spectrum2_000117
Spectrum3_000314
Spectrum4_000249
Spectrum5_000860
STK043620
Topcaine
UNII-U3RSY48JW5
WLN: ZR DVO2
ZINC12358719
|
|
6 |
|
Timolol |
Approved |
Phase 3 |
|
26839-75-8 |
33624
5478
|
Synonyms:
(-)-3-Morpholino-4-(3-tert-butylamino-2-hydroxypropoxy)-1,2,5-thiadiazole
(2S)-1-((1,1-dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol
(2S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
(2S)-1-[(1,1-dimethylethyl)amino]-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
(S)-1-(1,1-(Dimethylethyl)amino)-3-((4-(4-morpholinyl)-1,2,5-thiadiazol-3-yl)oxy)-2-propanol
(S)-1-(tert-Butylamino)-3-((4-morpholino-1,2,5-thiadiazol-3-yl)oxy)propan-2-ol
(S)-1-(tert-butylamino)-3-[(4-morpholin-4-yl-1,2,5-thiadiazol-3-yl)oxy]propan-2-ol
(S)-timolol
131628-37-0
194288-09-0
26839-75-8
26921-17-5 (maleate (1:1) salt)
AB00513729
AC1L1PYN
AC1Q59QM
Apo-Timol
Apo-Timop
Aquanil
Betim
Betimol
Betimol (TN)
BIDD:GT0073
Blocadren
BPBio1_001008
BRD-K08806317-050-03-6
BSPBio_000916
C07141
C13H24N4O3S
CAS-26921-17-5
CHEBI:9599
CHEMBL499
CID33624
CPD001456519
D08600
DB00373
DB08625
EINECS 248-032-6
HMS2089I11
HSDB 6533
Istalol
L-714,465
Lopac0_001189
Lopac-T-6394
LS-122231
MK-950
NCGC00016038-01
NCGC00016038-02
|
NCGC00016798-01
NCGC00016798-07
NCGC00022033-02
NCGC00022033-04
NCGC00022033-05
Novo-Timol
Nu-Timolol
Oprea1_640981
Optimol
Phoxal-timolol
Prestwick0_000948
Prestwick1_000948
Prestwick2_000948
Prestwick3_000948
Proflax
S-(-)-3-(3-tert-Butylamino-2-hydroxypropoxy)-4-morpholino-1,2,5-thiadiazole
S(-)-Timolol maleate
SAM002564238
SPBio_003075
ST072193
Temserin
Tenopt
TIM
Timacar
Timacor
Tim-AK
timolol
Timolol
Timolol (INN)
Timolol (TN)
Timolol [USAN]
Timolol anhydrous
Timolol GFS
Timolol maleate
Timolol Maleate, (1:1) Salt
Timololo
Timololum
Timololum [INN-Latin]
Timopic
Timoptic
Timoptic in Ocudose
Timoptic OcuDose
Timoptic-XE
Timoptol
Tocris-0649
UNII-817W3C6175
|
|
7 |
|
tannic acid |
Approved |
Phase 3 |
|
|
|
8 |
|
Carboplatin |
Approved |
Phase 3 |
|
41575-94-4 |
10339178
38904
498142
|
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
azanide
Blastocarb
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
Carbopaltin
Carboplat
carboplatin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Carbosin
Carbotec
Cbdca
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
Cyclobutane-1,1-dicarboxylate
cyclobutane-1,1-dicarboxylic acid
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
|
EINECS 255-446-0
Ercar
EU-0100230
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
IUPAC: Azane
JM 8
JM8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
Lopac0_000230
Lopac-C-2538
LS-117689
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
Nealorin
Neocarbo
NINDS_000892
NSC 201345
NSC 241240
NSC201345
NSC241240
NSC-241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
platinum(2+)
Platinum(II), (1, 1-cyclobutanedicar
Platinum, {diammine[1,1-cyclobut
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Ribocarbo
S1215_Selleck
SPBio_000716
Spectrum_001529
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
UNII-BG3F62OND5
|
|
9 |
|
Topotecan |
Approved, Investigational |
Phase 3 |
|
123948-87-8, 119413-54-6 |
60700
|
Synonyms:
(4S)-10-[(dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(S)-10-((Dimethylamino)methyl)-4-ethyl-4,9-dihydroxy-1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione
(S)-10-[(Dimethylamino)methyl]-4-ethyl-4,9-dihydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]-quinoline-3,14(4H,12H)-dione
(S)-10-[(DIMETHYLAMINO)METHYL]-4-ETHYL-4,9-DIHYDROXY-1H-PYRANO[3',4':6,7]INOLIZINO[1,2-B]-QUINOLINE-3,14(4H,12H)-DIONE
123948-87-8
9 Dimethylaminomethyl 10 hydroxycamptothecin
9-[(dimethylamino)Methyl]-10-hydroxy-(4S)-camptothecin
9-Dimethylaminomethyl-10-hydroxycamptothecin
AC-11592
AC1L1TQZ
AC1Q6APZ
BSPBio_002348
C11158
C23H23N3O5
CCRIS 8163
CHEBI:107501
CHEBI:46035
CHEMBL84
CID60700
D08618
DB01030
HMS2090B20
HSCI1_000228
Hycamptamine
Hycamptin
Hycamtamine
Hycamtin
Hycamtin (TN)
Hydrochloride, nogitecan
Hydrochloride, topotecan
LS-127395
MLS000759456
NCGC00178695-01
NChemBio.2007.10-comp24
|
NCI60_004771
NCIStruc1_001659
NCIStruc2_001796
Nogitecan hydrochloride
NSC609699
SK And F 104864 a
SK And F104864a
SK And F-104864-a
SK&F-104864-A
SKF 104864
SKF-104864-A
SKF-S 104864
SmithKline beecham brand OF topotecan hydrochloride
SMP2_000312
SMP2_000327
SMR000466344
TOPO
topotecan
Topotecan (BAN)
Topotecan [INN:BAN]
Topotecan Hcl
Topotecan hydrochloride
Topotecan Hydrochloride
Topotecan lactone
Topotecan Lactone
Topotecan monohydrochloride, (S)-isomer
Topotecan Monohydrochloride, (S)-Isomer
TOPOTECAN, HYCAMTIN
Topotecane
Topotecane [INN-French]
Topotecanum
Topotecanum [INN-Latin]
TPT
TTC
UNII-7M7YKX2N15
|
|
10 |
|
Antihypertensive Agents |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
11 |
|
Pharmaceutical Solutions |
|
Phase 3,Phase 2,Phase 1 |
|
|
|
12 |
|
Ophthalmic Solutions |
|
Phase 3,Phase 2,Phase 1,Early Phase 1 |
|
|
|
13 |
|
Neurotransmitter Agents |
|
Phase 3 |
|
|
|
14 |
|
Adrenergic Agents |
|
Phase 3 |
|
|
|
15 |
|
Anti-Arrhythmia Agents |
|
Phase 3 |
|
|
|
16 |
|
Adrenergic beta-Antagonists |
|
Phase 3 |
|
|
|
17 |
|
Adrenergic Antagonists |
|
Phase 3 |
|
|
|
18 |
|
Anti-Bacterial Agents |
|
Phase 2, Phase 3,Not Applicable |
|
|
|
19 |
|
Nucleic Acid Synthesis Inhibitors |
|
Phase 2, Phase 3,Not Applicable |
|
|
|
20 |
|
Antibiotics, Antitubercular |
|
Phase 2, Phase 3,Not Applicable |
|
|
|
21 |
|
Mitomycins |
|
Phase 2, Phase 3,Not Applicable |
|
|
|
22 |
|
Alkylating Agents |
|
Phase 2, Phase 3,Not Applicable |
|
|
|
23 |
|
topoisomerase I inhibitors |
|
Phase 3 |
|
|
|
24 |
|
Topoisomerase Inhibitors |
|
Phase 3 |
|
|
|
25 |
|
Latanoprost |
Approved, Investigational |
Phase 2 |
|
130209-82-4 |
5311221
5282380
|
Synonyms:
130209-82-4
AC1NSK8Q
Ambap130209-82-4
AR-202
Catioprost
CHEBI:6384
CHEMBL1051
CID5311221
CPD000466354
D00356
HMS2051H11
HMS2089J17
isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprost-5-en-1-oate
Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate
Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoic acid
Jsp001835
L1167_SIGMA
latanoprost
Latanoprost
Latanoprost (JAN/USAN/INN)
latanoprost free acid
Latanoprostum
MLS000759468
|
MLS001424106
MolPort-003-942-862
Nova-21027
Pfizer brand OF latanoprost
PhXA 41
PhXA34
PhXA34 [as 15(R,S)-isomer]
PhXA41
PHXA41
PHXA-41
propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
Propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate
Propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoic acid
propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate
S1254_Selleck
SAM001246671
SMR000466354
TL8000716
XA41
XA-41
Xalatan
Xalatan (TN)
Xalatan Fixed Flow Device
ZINC12468792
|
|
26 |
|
Dorzolamide |
Approved |
Phase 2 |
|
120279-96-1 |
5284549
3154
|
Synonyms:
(4S,6S)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide
(4S,6S)-4-(ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide
(4S,6S)-4-ethylamino-6-Methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonate amide
(4S,6S)-4-ethylamino-6-Methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide
(4S,6S)-4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide
(4S,6S)-4-ethylamino-6-Methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulphonate amide
(4S,6S)-4-ethylamino-6-Methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulphonic acid amide
(4S,trans)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide
(4S,trans)-4-(ethylamino)-6-Methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide
(4S,trans)-4-(Ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide
(4S,trans)-4-(ethylamino)-6-Methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulphonamide 7,7-dioxide
(4S-trans)-4-(ethylamino)-5,6-dihydro-6-METHYL-4H-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide
(4S-trans)-4-(ETHYLAMINO)-5,6-dihydro-6-methyl-4H-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide
(4S-TRANS)-4-(ETHYLAMINO)-5,6-DIHYDRO-6-METHYL-4H-THIENO(2,3-B)THIOPYRAN-2-SULFONAMIDE-7,7-DIOXIDE
(4S-trans)-4-(ethylamino)-5,6-dihydro-6-METHYL-4H-thieno(2,3-b)thiopyran-2-sulphonamide-7,7-dioxide
120279-96-1
1cil
4-ethylamino-5,6-dihydro-6-Methyl-7,7-dioxide-4H-thieno(2,3-b)thiopyran-2-sulfonamide
4-ethylamino-6-Methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonate amide
4-ethylamino-6-Methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide
4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulfonic acid amide
4-ethylamino-6-Methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulphonate amide
4-ethylamino-6-Methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda*6*-thieno[2,3-b]thiopyran-2-sulphonic acid amide
4-ethylamino-6-Methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulfonate amide
4-ethylamino-6-Methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulfonic acid amide
4-Ethylamino-6-methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulfonic acid amide
4-ethylamino-6-Methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulphonate amide
4-ethylamino-6-Methyl-7,7-dioxo-4,5,6,7-tetrahydro-7lambda6-thieno[2,3-b]thiopyran-2-sulphonic acid amide
4S,6S-Dorzolamide
5,6-dihydro-4-ethylamino-6-Methyl-4H-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide
AB00514687
|
AC1NR4NP
BIDD:GT0306
BPBio1_001377
BRD-K48617017-003-03-1
BSPBio_001252
C06969
CHEBI:4702
CHEMBL218490
CID5284549
D07871
DB04507
Dorzolamid
Dorzolamida
dorzolamide
Dorzolamide
Dorzolamide (DZA)
Dorzolamide (INN)
Dorzolamide chibret
Dorzolamide hydrochloride
Dorzolamide, (trans)-isomer
Dorzolamidum
HMS2089O06
MolPort-005-941-739
Prestwick0_001116
Prestwick1_001116
Prestwick2_001116
Prestwick3_001116
SPBio_003116
STK645522
Trusopt
Trusopt (TN)
|
|
27 |
|
Carbonic Anhydrase Inhibitors |
|
Phase 2 |
|
|
|
28 |
|
Tetracaine |
Approved, Vet_approved |
Early Phase 1 |
|
94-24-6 |
5411
|
Synonyms:
136-47-0 (mono-hydrochloride)
2-(dimethylamino)ethyl 4-(butylamino)benzoate
2-(Dimethylamino)ethyl 4-(butylamino)benzoate
2-(Dimethylamino)ethyl p-(butylamino)benzoate
2-dimethylaminoethyl 4-(butylamino)benzoate
2-Dimethylaminoethylester kyseliny p-butylaminobenzoove
2-Dimethylaminoethylester kyseliny p-butylaminobenzoove [Czech]
4-(Butylamino)benzoic acid 2-(dimethylamino)ethyl ester
4-[Butylamino]benzoic acid-2-[dimethylamino]ethyl ester
4-14-00-01172 (Beilstein Handbook Reference)
94-24-6
AB00053549
AC1L1KAQ
AC-3480
Amethocaine
Amethocaine (TN)
Amethocaine HCl
Anetain
Benzoic acid, 4-(butylamino)-, 2-(dimethylamino)ethyl ester
BENZOIC ACID, p-(BUTYLAMINO)-, 2-(DIMETHYLAMINO)ETHYL ESTER
BENZOIC ACID,4-BUTYLAMINO,2-DIMETHYLAMINOETHYL ESTER PANTOCAIN BASE
BPBio1_000422
BRD-K45071273-003-05-8
BRN 2216051
BSPBio_000382
BSPBio_001944
C07526
C15H24N2O2
CAS-136-47-0
CHEBI:9468
CHEMBL698
CID5411
Contralgin
D00551
Diaethylaminoaethanol ester der p-butylaminobenzoesaeure
Diaethylaminoaethanol ester der p-butylaminobenzoesaeure [German]
Diäthylaminoäthanol ester der p-butylaminobenzösäure
Dicain
Dicaine
Dikain
Dimethylaminoethyl p-butyl-aminobenzoate
DivK1c_000607
EINECS 202-316-6
Fissucain
I01-1872
IDI1_000607
InChI=1/C15H24N2O2/c1-4-5-10-16-14-8-6-13(7-9-14)15(18)19-12-11-17(2)3/h6-9,16H,4-5,10-12H2,1-3H
Intercain
KBio1_000607
KBio2_001512
KBio2_004080
KBio2_006648
KBio3_001444
|
KBioGR_000781
KBioSS_001512
Laudocaine
Lopac0_001211
Lopac-T-7508
LS-36312
Medicaine
Medihaler-Tetracaine
Meethobalm
Metraspray
MolPort-001-783-476
Mucaesthin
NCGC00016049-01
NCGC00016049-02
NCGC00016049-04
NCGC00162367-01
NINDS_000607
Niphanoid
p-(butylamino)benzoic acid β-(dimethylamino)ethyl ester
p-(Butylamino)benzoic acid, 2-(dimethylamino)ethyl ester
p-Butylaminobenzoyl-2-dimethylaminoethanol
Pontocaine
Prestwick0_000571
Prestwick1_000571
Prestwick2_000571
Prestwick3_000571
Rexocaine
SBB058194
SPBio_001455
SPBio_002601
Spectrum_001032
Spectrum2_001328
Spectrum3_000562
Spectrum4_000351
Spectrum5_001072
T3812_SIAL
T7383_SIAL
T7383_SIGMA
Tetracaina
Tetracaína
Tetracaina [INN-Spanish]
tetracaine
Tétracaïne
Tetracaine (USP/INN)
Tetracaine [USAN:INN]
Tetracaine HCl
Tetracainum
Tetracainum [INN-Latin]
Tetrakain
Tetrakain [Czech]
UNII-0619F35CGV
Uromucaesthin
|
|
29 |
|
Sevoflurane |
Approved, Vet_approved |
Early Phase 1 |
|
28523-86-6 |
5206
|
Synonyms:
1,1,1,3,3,3-hexafluoro-2-(Fluoromethoxy)propane
1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane
28523-86-6
AC-15484
AC1L1JU0
Bax 3084
BRN 2041023
C009250
C07520
C4H3F7O
CHEBI:9130
CHEMBL1200694
CID5206
D00547
DB01236
F0691
Fluoromethyl 1,1,1,3,3,3-Hexafluoroisopropyl Ether
Fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
fluoromethyl hexafluoroisopropyl ether
Fluoromethyl hexafluoroisopropyl ether
fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
Fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether
I14-13357
|
LS-67851
MolPort-001-775-746
MR_6S4
MR6S4
NCGC00167421-01
PC4681
Sevofluran
sevoflurane
Sevoflurane
Sevoflurane (JAN/USAN/INN)
Sevoflurane [USAN:INN:BAN:JAN]
Sevoflurano
Sevoflurano [INN-Spanish]
Sevofluranum
Sevofluranum [INN-Latin]
Sevofrane
Sevorane
Sojourn
Ultane
Ultane (TN)
UNII-38LVP0K73A
ZINC01530810
|
|
30 |
|
Nitrous oxide |
Approved, Vet_approved |
Early Phase 1 |
|
10024-97-2 |
948
|
Synonyms:
00583_FLUKA
10024-97-2
126386-65-0
129451-49-6
130835-71-1
147527-07-9
175876-44-5
295590_ALDRICH
794457-85-5
847968-13-2
850203-00-8
AC1L1ADZ
C00887
CCRIS 1225
CHEBI:17045
CHEMBL1234579
CID948
D00102
D009609
Diazyne 1-oxide
Dinitrogen monoxide
Dinitrogen oxide
Distickstoffmonoxid
e942
EINECS 233-032-0
Factitious air
FEMA 2779
FEMA No. 2779
Gas, laughing
Gas, Laughing
gaz hilarant
Gaz hilarant
HSDB 504
Hyponitrous acid anhydride
Lachgas
Laughing gas
LS-7622
N2O
Nitral
Nitrious oxide
|
Nitrogen hypoxide
Nitrogen monoxide
Nitrogen oxide (N2O)
Nitrogen protoxide
nitrogenium oxydulatum
Nitrogenium oxydulatum
nitrous oxide
Nitrous oxide (JP15/usp)
Nitrous oxide (JP15/USP)
Nitrous oxide (TN)
Nitrous oxide [Anaesthetics, volatile]
Nitrous oxide [JAN]
Nitrous oxide [UN1070] [Nonflammable gas]
Nitrous oxide [UN1070] [Nonflammable gas]
Nitrous oxide, compressed
Nitrous oxide, jan, usan
Nitrous oxide, refrigerated liquid
Nitrous oxide, refrigerated liquid [UN2201] [Nonflammable gas]
Nitrous oxide, refrigerated liquid [UN2201] [Nonflammable gas]
Nitrous-oxide
NITROUS-OXIDE
NNO
Oxide, nitrous
Oxide, Nitrous
oxido Nitroso
Oxido nitroso
Oxido nitroso [Spanish]
oxidodinitrogen(N--N)
Oxidodinitrogen(N--N)
oxyde nitreux
Oxyde nitreux
protoxyde d'azote
Protoxyde d'azote
Protoxyde d'azote [French]
R-744a
Stickdioxyd
Stickdioxyd [German]
Stickstoff(I)-oxid
UN1070
UN2201
|
|
31 |
|
Peripheral Nervous System Agents |
|
Early Phase 1 |
|
|
|
32 |
|
Central Nervous System Depressants |
|
Early Phase 1 |
|
|
|
33 |
|
Anesthetics |
|
Early Phase 1 |
|
|
|
34 |
|
Anesthetics, Local |
|
Early Phase 1 |
|
|
|
35 |
|
Analgesics |
|
Early Phase 1 |
|
|
|
36 |
|
Platelet Aggregation Inhibitors |
|
Early Phase 1 |
|
|
|
37 |
|
Analgesics, Non-Narcotic |
|
Early Phase 1 |
|
|
|
38 |
|
Anesthetics, General |
|
Early Phase 1 |
|
|
|
39 |
|
Anesthetics, Inhalation |
|
Early Phase 1 |
|
|
|
Interventional clinical trials:
(show all 23)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Comparison of the Ahmed Glaucoma Valve FP7 and FP8 in Pediatric Glaucoma |
Unknown status |
NCT01494974
|
Phase 4 |
|
2 |
Use of Bevacizumab in Trabeculectomy Surgery |
Completed |
NCT01166594
|
Phase 4 |
Bevacizumab;Control |
3 |
Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients |
Completed |
NCT01652664
|
Phase 3 |
Travoprost 0.004% PQ ophthalmic solution;Timolol, 0.5% or 0.25% ophthalmic solution;Travoprost Vehicle |
4 |
Trabeculectomy With MMC Versus Ahmed Glaucoma Implant for Treatment of Pediatric Aphakic Glaucoma |
Completed |
NCT00371072
|
Phase 2, Phase 3 |
|
5 |
Treatment Protocol for Non-Metastatic Unilateral Retinoblastoma |
Recruiting |
NCT03475121
|
Phase 3 |
|
6 |
Efficacy and Safety of Topically Applied Medical Therapy for the Treatment of Pediatric Glaucoma |
Unknown status |
NCT01527682
|
Phase 2 |
Latanoprost, Dorzolamide |
7 |
Combined Trab+Trab Versus Combined Trab+Trab With Subconjunctival Implantation of Ologen for Primary Congenital Glaucoma |
Unknown status |
NCT02121171
|
Phase 1 |
|
8 |
Comparison Between Deep Sclerectomy and Traditional Trabeculotomy & Trabeculectomy in Congenital Glaucoma |
Unknown status |
NCT01460017
|
Phase 1 |
|
9 |
Pharmacokinetic and Safety Study of Travoprost 0.004% in Pediatric Glaucoma Patients |
Completed |
NCT01658839
|
Phase 1 |
Travoprost ophthalmic solution, 0.004% (new formulation) |
10 |
The Genetic Characteristics in South Korean Patients With Primary Congenital Glaucoma |
Unknown status |
NCT01020721
|
|
|
11 |
Endoscopic Goniotomy for Infantile Glaucoma |
Completed |
NCT00338533
|
Not Applicable |
|
12 |
Quality of Life in Children Glaucoma and Cataract |
Completed |
NCT02490267
|
|
|
13 |
The Measurement of Intraocular Pressure in Normal Children Under General Anesthesia With and Without Nitrous Oxide and Anesthetic Eye Drops |
Completed |
NCT01925391
|
Early Phase 1 |
Tono-pen XL Applanation tonometer + Ocu-film + |
14 |
Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation |
Completed |
NCT02945176
|
Not Applicable |
|
15 |
Evaluation and Treatment of Pediatric, Developmental, and Genetic Eye Diseases |
Completed |
NCT00076271
|
|
|
16 |
mRNA Expression in Lymphocytes of Glaucoma Patients |
Completed |
NCT00327509
|
|
|
17 |
Prospective Study of the Diagnostic and Therapeutic Management of Congenital Glaucoma in France |
Recruiting |
NCT03077789
|
Not Applicable |
|
18 |
Genetic Testing in Primary Congenital Glaucoma Patients |
Recruiting |
NCT01136460
|
|
|
19 |
Determination of the Sensitivity and Specificity of a Smartphone Application to Detect Retinoblastoma |
Recruiting |
NCT03016156
|
Not Applicable |
|
20 |
Aqueous Humor Dynamics and Biometric Parameters in Eyes of Children |
Recruiting |
NCT01290588
|
|
|
21 |
Repository for Inherited Eye Diseases |
Active, not recruiting |
NCT00378742
|
|
|
22 |
Ologen® Collagen Matrix in Patients With Primary Congenital Glaucoma Undergoing Trabeculectomy |
Not yet recruiting |
NCT03541551
|
Not Applicable |
|
23 |
Ologen® Collagen Matrix Versus Mitomycin-C in Patients With Juvenile-onset Open Angle Glaucoma |
Not yet recruiting |
NCT03548805
|
Not Applicable |
|
|